"We’re in this with you, to help you get the care you need, safely. Vanderbilt Health has restarted surgeries, procedures and clinic visits that were paused or delayed. Safety is our top priority, with measures that follow – and in some cases exceed – local, state and CDC public health recommendations. Everyone wears a mask – patients, visitors, doctors, nurses and staff. We’re sanitizing rooms between each patient, and cleaning public spaces frequently throughout the day. We’re checking everyone for fever and symptoms before they enter our facilities. We’ve spaced chairs in waiting areas, limited the number who can ride elevators at once and made other changes so we can keep a safe (6 feet) physical distance."

During the past decade, Vanderbilt Breast Center at One Hundred Oaks conducted 71 clinical trials. In the 10-year time frame, 71 clinical trials started and 27 clinical trials were completed, i.e. on average, 38% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 22 clinical trials were completed. i.e. 137.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vanderbilt Breast Center at One Hundred Oaks" #1 sponsor was "National Cancer Institute (NCI)" with 41 trials, followed by "SWOG Cancer Research Network" with 15 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 7 trials sponsored, "Alliance for Clinical Trials in Oncology" with 6 trials sponsored and "NRG Oncology" with 6 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vanderbilt Breast Center at One Hundred Oaks" #1 collaborator was "National Cancer Institute (NCI)" with 34 trials as a collaborator, "Canadian Cancer Trials Group" with 5 trials as a collaborator, "NRG Oncology" with 4 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "Astellas Pharma Inc" with 2 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Vanderbilt Breast Center at One Hundred Oaks" are "Invasive Breast Carcinoma" (10 trials), "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Breast Cancer" (7 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials) and "Stage IIIA Breast Cancer" (5 trials). Many other conditions were trialed in "Vanderbilt Breast Center at One Hundred Oaks" in a lesser frequency.

Most popular intervention types in "Vanderbilt Breast Center at One Hundred Oaks" are "Drug" (60 trials), "Other" (43 trials), "Procedure" (36 trials), "Biological" (30 trials) and "Radiation" (7 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (25 trials), "Biospecimen Collection" (21 trials), "Computed Tomography" (17 trials), "Nivolumab" (13 trials) and "Quality-of-Life Assessment" (13 trials). Other intervention names were less common.

The vast majority of trials in "Vanderbilt Breast Center at One Hundred Oaks" are 67 trials for "All" genders, 14 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Vanderbilt Breast Center at One Hundred Oaks". undefined are not yet recruiting, 19 are recruiting, 44 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Vanderbilt Breast Center at One Hundred Oaks, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Vanderbilt Breast Center at One Hundred Oaks, 6 "Phase 1" clinical trials were conducted, 44 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".

Vanderbilt Breast Center at One Hundred Oaks has several departments that took part in Clinical trials: "Vanderbilt Heart and Vascular Institute" - 23 trials, "Vanderbilt University Medical Center - IBD Clinic" - 12 trials, "Vanderbilt University Medical Center - Digestive Disease Center" - 12 trials, "Vanderbilt Orthopaedic Institute" - 10 trials, "Vanderbilt Eskind Diabetes Clinic" - 8 trials, "Vanderbilt University Medical Center - Infectious Diseases" - 8 trials, "Vanderbilt Epilepsy Clinic" - 4 trials, "Vanderbilt University Medical Center Emergency Medicine" - 4 trials, "Vanderbilt Medical Center - IPF Center" - 2 trials, "Vanderbilt Comprehensive Multiple Sclerosis Center" - 2 trials, "Vanderbilt University Hospital Pharmacy" - 2 trials, "Vanderbilt Cancer Clinic" - 2 trials, "Division of Hematology/Stem Cell Transplant" - 2 trials, "Vanderbilt University Medical Center Vanderbilt Clinical Neurosciences" - 2 trials